EGFR and neoplasm: In selected cases where material and assays were available, it was possible to confirm the new variants identified in plasma, thus confirming that they are not sequence artifact but rather reflect an higher heterogeneity of EGFR mutant tumors as compared to what revealed by tumor tissue analyses.